{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/paronychia-acute/prescribing-information/flucloxacillin/","result":{"pageContext":{"chapter":{"id":"a2fead58-dca1-5103-8ad8-61ea6110cd3e","slug":"flucloxacillin","fullItemName":"Flucloxacillin","depth":2,"htmlHeader":"<!-- begin field db3ae54d-000d-4b12-8452-f9a909db7b0e --><h2>Flucloxacillin</h2><!-- end field db3ae54d-000d-4b12-8452-f9a909db7b0e -->","summary":"","htmlStringContent":"<!-- begin item a9595c9c-74cf-452a-b300-dbf32b725cec --><!-- end item a9595c9c-74cf-452a-b300-dbf32b725cec -->","topic":{"id":"b2bb7fc0-a6db-5872-b76f-83f50e0814ee","topicId":"6c8ca646-4291-4610-b32e-02c43d2c8af9","topicName":"Paronychia - acute","slug":"paronychia-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"9d232456-a0db-59c3-81d2-6066b705f267","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e855a6e8-ed6f-50da-8601-bb658a2c2142","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b7baf273-3ab9-5b99-91b1-7ff165d7b93e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"118743c0-8ede-55bf-b84a-3f9b8fcebdd8","slug":"changes","fullItemName":"Changes"},{"id":"4ba6812b-5e78-5829-a1ca-8f8a57fe62b4","slug":"update","fullItemName":"Update"}]},{"id":"d477c411-32be-55fe-a86e-08290f4d2b8e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8c33920b-b3ac-508f-b75a-1eff779e03a1","slug":"goals","fullItemName":"Goals"},{"id":"c4185e18-cda2-5c32-93a0-5c296bd5c060","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f88d0725-e6fd-5377-81c4-23ab93a7caf9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4f840bc1-0fc7-584f-873e-932c373ceada","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1532db75-44de-553a-9f1e-252b405093a2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"36684520-6e5e-55c7-9b20-a4036334ed13","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a51d8911-5c44-5fbe-891f-7a1ce243e2d0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3b0bcedc-02f6-597c-91c1-68ad812ee098","slug":"definition","fullItemName":"Definition"},{"id":"dbf72d8a-9d7c-5237-9ec4-41564c1723a2","slug":"causes","fullItemName":"Causes"},{"id":"27706fc3-d0b2-517c-a4ca-f9c337526f6e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"693a21f1-8661-5aa0-a4ad-4fd293690c1f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a7b667a2-77ed-58ce-85e1-28053b3cbac6","slug":"complications","fullItemName":"Complications"},{"id":"69b0affa-ba11-50c0-b7eb-4164215fff81","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"402635e2-8b5b-510b-8911-de663be26627","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d2b9d442-db59-5ce2-8001-f79b47a0d07b","slug":"clinical-presentation","fullItemName":"Clinical presentation"},{"id":"5fefa9cc-3cd1-5fe6-97c9-b95e84cf7790","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d056845a-158d-5904-925f-c1f2590f7c8c","fullItemName":"Management","slug":"management","subChapters":[{"id":"2f065baa-02b7-57a9-a6f9-036079cc78af","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b8188aa3-5a20-53fc-9ac5-f1500bcb20ee","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2fead58-dca1-5103-8ad8-61ea6110cd3e","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0ba4b7a5-9a25-5970-b668-a9c7c4fb38af","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"17d25ace-76d2-5ab6-ac1d-8a1238ea8e09","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"6e2d0756-59aa-5521-b157-730945914705","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f5ecaf87-1d35-5c33-8736-46baa81bda4e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9235cf50-84ce-54e7-b840-58aa133fc328","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"592eaa54-938e-528f-ac4e-1f2d1e7bf7b7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"37214d7d-d933-54be-90ef-dc6fabcc7943","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"599ff9f8-a29d-5b76-9429-6e0788baf48f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a58d49de-b64c-5e6e-8c5b-5c60f36f832c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2bc165bd-1fb7-56b2-8b43-476ce2b9c4a2","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b8188aa3-5a20-53fc-9ac5-f1500bcb20ee","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"51273285-d6b5-5767-9813-4979b1d9cda3","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field d3fa7add-42cb-4c07-8b85-0b3cc8ba6555 --><h3>Dose</h3><!-- end field d3fa7add-42cb-4c07-8b85-0b3cc8ba6555 -->","summary":"","htmlStringContent":"<!-- begin item 930d9fa8-0aec-46a5-baaf-bd88272cac98 --><!-- begin field 70c78e1c-68e2-43ed-bd0c-0d39a6a97fbf --><ul><li>Adults and children older than 10 years of age — 250 mg to 500 mg, four times a day for 7 days.</li><li>Children 2–9 years of age — 125 mg to 250 mg, four times a day for 7 days.</li><li>Children 1 month to 1 year of age — 62.5 mg to 125 mg, four times a day for 7 days.<ul><li>Oral flucloxacillin is available as 250 mg and 500 mg capsules, and 125 mg per 5 mL and 250 mg per 5 mL oral solution.</li></ul></li><li>The recommendations on length of antibiotics course are extrapolated from an antibiotics guideline produced by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">PHE, 2017</a>].<ul><li>PHE did not consider the treatment of acute paronychia but for other bacterial skin infections, such as impetigo and cellulitis, they recommend a duration of 7 days for empirical antibiotic treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">PHE, 2017</a>].</li></ul></li><li>CKS found no randomized controlled trials that studied the effectiveness of antibiotic treatment (or the length of antibiotic course needed) for the treatment of acute paronychia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>]</p><!-- end field 70c78e1c-68e2-43ed-bd0c-0d39a6a97fbf --><!-- end item 930d9fa8-0aec-46a5-baaf-bd88272cac98 -->","subChapters":[]},{"id":"9076ce9d-d7fe-5714-8f82-a7c409c26b22","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field afeb6984-eb6b-454a-b751-a76e00c11a1c --><h3>Adverse effects</h3><!-- end field afeb6984-eb6b-454a-b751-a76e00c11a1c -->","summary":"","htmlStringContent":"<!-- begin item 4883bf6c-6b4b-4d73-a719-a76e00c117a2 --><!-- begin field 892381f8-0b6f-4e68-8f0f-a76e00c11a1c --><ul><li><strong>Common adverse effects of flucloxacillin include:</strong><ul><li>Gastrointestinal disturbances.</li><li>Joint pains.</li><li>Serum sickness-like reaction.</li><li>Allergic reactions such as rashes and anaphylaxis occur in 1–10% of people treated with penicillins.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Antibiotic-associated colitis.</li><li>Cholestatic jaundice and hepatitis occurs very rarely up to several weeks after treatment with flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors.</li><li>Cerebral irritation, CNS toxicity, encephalopathy.</li><li>Coagulation disorders.</li><li>Haemolytic anaemia, leukopenia, thrombocytopenia.</li><li>Interstitial nephritis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>]</p><!-- end field 892381f8-0b6f-4e68-8f0f-a76e00c11a1c --><!-- end item 4883bf6c-6b4b-4d73-a719-a76e00c117a2 -->","subChapters":[]},{"id":"676004fb-39e0-5783-b5a1-cba042ccf478","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8dd0fc6f-c711-4c5b-8f24-a76e00c1336e --><h3>Contraindications and cautions</h3><!-- end field 8dd0fc6f-c711-4c5b-8f24-a76e00c1336e -->","summary":"","htmlStringContent":"<!-- begin item b3c7fb95-cd51-4d8a-99c4-a76e00c13163 --><!-- begin field 5ad8c915-5af8-41ac-965e-a76e00c1336e --><ul><li><strong>Do not prescribe flucloxacillin to people with:</strong><ul><li>A history of hypersensitivity (including anaphylaxis, urticaria or rash immediately after administration) to beta-lactam antibiotics such as penicillins or cephalosporins.</li><li>A history of flucloxacillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe flucloxacillin with caution to people with:</strong><ul><li>Hepatic dysfunction (not flucloxacillin related), especially if they are 50 years or over, or have a serious underlying disease.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">CSM, 2004a</a>] </p><!-- end field 5ad8c915-5af8-41ac-965e-a76e00c1336e --><!-- end item b3c7fb95-cd51-4d8a-99c4-a76e00c13163 -->","subChapters":[]},{"id":"93ad3ada-8f92-52af-a0ae-321bcf1a0404","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6b36807f-49fc-4b8c-9d00-a76e00c14b1b --><h3>Drug interactions</h3><!-- end field 6b36807f-49fc-4b8c-9d00-a76e00c14b1b -->","summary":"","htmlStringContent":"<!-- begin item 692c7636-05da-4faa-bbcd-a76e00c1493b --><!-- begin field 1196172d-0ba1-4a7c-a045-a76e00c14b1b --><p><strong>Drug interactions with flucloxacillin include:</strong></p><ul><li>Food — flucloxacillin should be taken one hour before food or on an empty stomach.</li><li>Anticoagulants such as warfarin — monitor INR so that changes in anticoagulant effects can be identified and corrected.</li><li>Methotrexate — consider monitoring as there have been rare reports of reduced clearance and acute methotrexate toxicity with concurrent use. One recommended approach is to carry out twice-weekly platelet and white cell count for 2 weeks initially and measure methotrexate levels if toxicity is suspected.</li><li>Oral hormonal contraception — additional contraceptive precautions are <em>not </em>required during or after courses of flucloxacillin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">FSRH, 2017</a>]</p><!-- end field 1196172d-0ba1-4a7c-a045-a76e00c14b1b --><!-- end item 692c7636-05da-4faa-bbcd-a76e00c1493b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}